![[마감] 코스피, 기관 매수에 1%대 상승…2530선 안착](https://i-invdn-com.investing.com/news/KOSPI_150x108_S_1625084172.jpg)
선호 종목, 경제 이벤트, 팔로우하는 저자들의 글 업데이트를 받으시려면 회원가입을 해주세요.
무료 회원가입 이미 계정이 있으세요? 로그인
22.100
+0.330
+1.52%
👀 주목해야 할 종목: 지금 바로 매수해야 할 가장 저평가된 주식!
저평가 종목 확인하기
BlackRock Global Funds - World Healthscience Fund A2 AUD Hedged (0P000127R4)
포토폴리오 추가/삭제
포트폴리오에 추가합니다
22/11 - 지연 데이터. AUD 통화
- 모닝스타 평가:
- 총 자산: 71.23M
종류:
펀드
시장:
룩셈부르크
발행자:
BlackRock (Luxembourg) SA
ISIN:
LU1023059063
자산등급:
주식
BlackRock Global Funds - World Healthscience Fund
22.100
+0.330
+1.52%
0P000127R4 개요
이 페이지에서 BlackRock Global Funds - World Healthscience Fund A2 AUD Hedged에 대한 상세 프로필을_x0008_ 확인해 보세요. 0P000127R4의 주요 관리, 총 자산, 투자 전략 및 연락처 정보에 대해 알아보세요.
투자 전략
"보건, 의약품, 의료기술 및 부품과 생명공학 개발 분야를 주된 경제활동으로 하는 회사의 주식에70% 이상 투자"
연락처
주소
35 A, avenue J.F. Kennedy,
Luxembourg, L-1855
Luxembourg
Luxembourg, L-1855
Luxembourg
전화
+44 20 77433000
팩스
Amsterdam
최고 경영진
| 종목명 | 헤드라인 | 재직 시작연도 | 기간 |
|---|---|---|---|
| Xiang Liu | Director | 2020 | now |
| 전기 | Xiang Liu, PhD, Director, is a member of the Health Sciences team, part of BlackRock’s Active Equity Group. He is co-portfolio manager for the Health Sciences equity portfolios and is responsible for coverage of the medical devices & supplies sector. Prior to joining BlackRock in 2008, Mr. Liu was a partner and biotech analyst at Mehta Partners. From 2002 to 2005, he was a Director in the corporate development department at Cubist Pharmaceuticals. Mr. Liu began his investment career in 2000 at the Boston Consulting Group as a Healthcare consultant. Mr. Liu earned a BS degree in Chemistry from the University of Science & Technology, China in 1993, a PhD degree in Chemistry from Yale University in 1997, and a MBA degree in finance, strategy, and accounting from the University of Chicago in 2000. | ||
| Erin Xie | Managing Director | 2011 | now |
| 전기 | Erin Xie, PhD, Managing Director and portfolio manager, is the head of the Health Sciences team, part of BlackRock’s Active Equity Group. She is the lead portfolio manager for the Health Sciences equity portfolios. Ms. Xie's service with the firm dates back to 2001, including her years with State Street Research & Management (SSRM), which merged with BlackRock in 2005. At SSRM, she was a Senior Vice President and portfolio manager responsible for managing the State Street Health Sciences Fund. Prior to joining State Street Research in 2001, Ms. Xie was a research associate with Sanford Bernstein covering the pharmaceutical industry from 1999. From 1994 until 1997, she was a post doctoral research scientist at Columbia University. Ms. Xie earned a BS degree in chemistry from Beijing University in 1988, a PhD degree in Biochemistry from the University of California, Los Angeles, in 1993 and a MBA degree from the Massachusetts Institute of Technology Sloan School of Management in 1999. | ||
| Jeff Lee | - | 2020 | 2023 |
| 전기 | Jeffrey Lee, Director, is a member of the Health Sciences team, part of BlackRock’s Active Equity Group. He is co-portfolio manager for the Health Sciences equity portfolios and is responsible for coverage of the healthcare providers and services sector. Prior to joining BlackRock in 2011, Mr. Lee was a member of the healthcare investment team at Duquesne Capital Management where he covered provider and service companies. From 2006 to 2008, Mr. Lee was an healthcare private equity associate at Altaris Capital Partners where he sourced and analyzed equity transactions for public and private healthcare companies. Prior to 2006, Mr. Lee was an analyst at Citigroup within the healthcare finance and investment banking group where he valued and helped structured financing for managed care providers, hospital companies and other large healthcare systems. Mr. Lee earned a BA degree in economics, cum laude, from Princeton University in 2004. | ||
| Thomas P. Callan | Managing Director | 2011 | 2017 |
| 전기 | Thomas P. Callan, CFA, Managing Director and senior portfolio manager, is head of BlackRock's Global Opportunities equity team. He oversees the team's investment process, leads the team's Investment Strategy Group, and provides portfolio and risk management oversight for all of the team's products. In addition, Mr. Callan is a member of BlackRock's Leadership Committee. Mr. Callan's service with the firm dates back to 1988, including his years with PNC Asset Management Group, which was integrated with BlackRock in 1998. He started as a health care analyst for PNC's mutual fund group and later served as an international equity analyst. Mr. Callan began his investment career at PNC Bank as a personal trust portfolio manager in 1988. Mr. Callan earned a BA degree in economics, with honors, from Boston College in 1981. | ||
| Bob Hodgson | - | 2005 | 2011 |
고객님의 BlackRock Global Funds - World Healthscience Fund A2 AUD Hedged에 대한 생각을 적어 주십시오.
이 차트를 삭제하시겠습니까?
삭제 취소
첨부된 차트를 새 차트로 교체할까요?
교체 취소
의견 지침
의견에 차트 첨부하기
차단 확인
%USER_NAME%(을)를 정말로 차단하시겠습니까?
그렇게 하면, 귀하와 %USER_NAME%(은)는 서로의 Investing.com 게시물을 볼 수 없습니다.
%USER_NAME%(은)는 차단 명단에 추가되었습니다.
방금 이 사람을 차단해제하였으므로 48시간 이후에 차단을 재개할 수 있습니다.
이 의견 보고하기
나는 이 의견이 다음과 같다고 생각합니다:
의견에 깃발 표시됨
감사합니다!
귀하의 보고는 검토를 위해 조정자에게 보내졌습니다.